Mariner’s Edgewise Therapeutics EWTX Stock Holding History

Mariner’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-18,211	Closed	-$141K	–	2938
2023 Q2	$141K	Buy	+18,211	New	+$154K	﹤0.01%	2567

Other funds holding EWTX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Mariner's EWTX Position: Q3 2023 in Review

Mariner sold out of Edgewise Therapeutics (EWTX) in Q3 2023, closing a stake of 18,211 shares — an estimated $141K sold.

Mariner first reported a position in EWTX in Q2 2023 and held it in 1 quarter. The position peaked at $141K in Q2 2023. 85 funds tracked by Wall St. Rank hold EWTX as of Q3 2023.

Mariner reported no remaining Edgewise Therapeutics position as of Q3 2023 after selling out during the quarter.
Mariner sold 18,211 Edgewise Therapeutics shares in Q3 2023, an estimated $141K.
Mariner first reported a position in Edgewise Therapeutics in Q2 2023 and held it in 1 quarter.
Mariner's Edgewise Therapeutics position peaked at $141K in Q2 2023.
85 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2023.

Based on Mariner's 13F filing for Q3 2023, filed 13 Nov 2023.